SCHEMBL2805552

SCHEMBL2805552

c1ccc(CNc2ncc3c(n2)CCc2cnc4[nH]ncc4c2-3)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCNA2 P20248 4/20 0.44
CDK2 P24941 4/20 0.44
CCNA1 P78396 2/20 0.44
AURKA O14965 1/20 0.44
IDO1 P14902 1/20 0.42
TDO2 P48775 1/20 0.42
PTK2 Q05397 5/20 0.40
PTK2B Q14289 3/20 0.40
IGF1R P08069 3/20 0.38
FGFR1 P11362 3/20 0.38
KDR P35968 2/20 0.38
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
HTT P42858 1/20 0.37
HDAC3 O15379 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC2 Q92769 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
MEN1 O00255 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2803917 0.82 ALDH1A1 (0.42) CCNA2CDK2IGF1RHTTHDAC3
SCHEMBL2802884 0.82 CDK2 (0.47) CCNA2CDK2CCNA1AURKAIGF1R
SCHEMBL2803843 0.80 CCNA2 (0.42) CCNA2CDK2IGF1RHDAC3HDAC1
SCHEMBL2804807 0.80 SLC29A1 (0.42) CCNA2CDK2IGF1R
SCHEMBL2806420 0.80 CDK2 (0.39) CCNA2CDK2ALDH1A1KDM4E
SCHEMBL2802228 0.78 AKT1 (0.38) CCNA2CDK2CCNA1AURKAHTT
SCHEMBL2804059 0.78 DYRK1A (0.48) AURKAALDH1A1MAOB
SCHEMBL2805136 0.77 LCK (0.41) CCNA2CDK2MEN1ALDH1A1KMT2A
SCHEMBL2486661 0.77 CCNA2 (0.38) CCNA2CDK2AURKA
SCHEMBL2806333 0.77 RPS6KB1 (0.54) CCNA2CDK2CCNA1AURKAIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-8263610-B2 Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds ARQULE, INC. (US) 2012-09-11 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS ARQULE, INC. (US) 2010-09-23 US disclosed
WO-2010078427-A1 SUBSTITUTED PYRAZOLO [3, 4-B] PYRIDINE COMPOUNDS ARQULE, INC. (US) 2010-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100239526-A1 SUBSTITUTED IMIDAZOLYL-5,6-DIHYDROBENZO[N]ISOQUINOLINE COMPOUNDS NQO1, IDH3B, IDH1 CCNA2 306/4885CDK2 46/4885CCNA1 244/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.